SINTSintx Technologies, Inc.
Sintx Technologies, Inc., an advanced ceramics company, engages in the research, development, and commercialization of medical devices manufactured with silicon nitride for biomedical, technical, and antipathogenic appli…
Industry Peers
Medical Devices| Headline | Source | Time |
|---|---|---|
Older | ||
 SINTX TECHNOLOGIES (SINT) Moves to Buy: Rationale Behind the Upgrade SINTX TECHNOLOGIES (SINT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. | ||
 Sintx Technologies, Inc. Q2 2026 Earnings Call Summary Moby summary of Sintx Technologies, Inc.'s Q2 2026 earnings call | ||
SINTX Technologies Inc (SINT) (Q2 2026) Earnings Call Highlights: Revenue Surges 199% as ... SINTX Technologies Inc (SINT) reports strong product revenue growth and improved margins, while managing liquidity challenges and advancing its SINAPTIC medical platform. | ||
 LivaNova (LIVN) Q2 Earnings and Revenues Beat Estimates LivaNova (LIVN) delivered earnings and revenue surprises of +16.67% and +2.90%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock? | ||
 ClearPoint Neuro, Inc. (CLPT) Reports Q2 Loss, Misses Revenue Estimates ClearPoint Neuro (CLPT) delivered earnings and revenue surprises of -31.03% and -16.31%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock? | ||
 AxoGen (AXGN) Tops Q2 Earnings and Revenue Estimates AxoGen (AXGN) delivered earnings and revenue surprises of +33.33% and +4.31%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock? | ||
 PAVmed Inc. (PAVM) Reports Q1 Loss, Lags Revenue Estimates PAVmed (PAVM) delivered earnings and revenue surprises of -69.57% and -78.00%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock? | ||
 Rapid Micro Biosystems, Inc. (RPID) Reports Q1 Loss, Tops Revenue Estimates Rapid Micro Biosystems (RPID) delivered earnings and revenue surprises of -24.00% and +6.69%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock? | ||
 Envoy Medical, Inc. (COCH) Reports Q3 Loss, Misses Revenue Estimates Envoy Medical, Inc. (COCH) delivered earnings and revenue surprises of -29.63% and -23.64%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock? | ||